ASRT insider trading
HealthcareAssertio Holdings, Inc.: insider trade history from SEC Form 4 filings.
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Company website: www.assertiotx.com
ASRT insider activity at a glance
FilingIQ tracks 295 insider transactions for ASRT in filings since Dec 4, 2018. The most recent transaction is dated Jun 16, 2026.
Across the full history, 23 open-market purchases
and 24 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ASRT insider trades is 66.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ASRT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ASRT?
- FilingIQ tracks 295 Form 4 insider transactions for ASRT (Assertio Holdings, Inc.), covering filings from Dec 4, 2018 onwards. 0 of those are dated within the last 90 days.
- Are ASRT insiders net buyers or net sellers?
- Across the full Form 4 history for ASRT, 23 transactions (8%) were open-market purchases and 24 (8%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ASRT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ASRT in?
- Assertio Holdings, Inc. (ASRT) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $77.30M.
Methodology & sources
Every ASRT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.